Blinding Integrity and Psychedelic Drug Trials

Дата публикации: 01-10-2026 00:00:00

To the Editor We read with interest the recent trial in JAMA Psychiatry of inhaled mebufotenin (GH001) for treatment-resistant depression. Compared with placebo, GH001 showed a significantly greater reduction in depressive symptoms at day 8 and a higher remission rate (23 of 40 patients treated with GH001 [57.5%] vs 0 of 41 patients treated with placebo [0%]).

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Blinding Integrity and Psychedelic Drug Trials	0	12.75	01-10-2026
2	Blinding Integrity and Psychedelic Drug Trials—Reply	0	7.17	01-10-2026
3	Depression and SSRI Treatment During Pregnancy	0	8.77	01-10-2026
4	ASTRO: Stereotactic Radiosurgical Capsulotomy Promising in Treatment-Resistant Depression	0	15.62	07-10-2026
5	Dépression : la révolution des traitements express	0	7.24	05-09-2026
6	Минздрав представил обновленный стандарт лечения депрессии	0	10	27-09-2026
7	Электростимуляция мозга дала быстрый эффект при тяжелой шизофрении	-1	8.46	03-10-2026
8	A Digital Therapeutic Intervention for Negative Symptoms of Schizophrenia	0	7.14	25-09-2026
9	How Should We Interpret the Association Between Abortion and Mild Psychiatric Illness?	0	7.52	01-10-2026
10	HI-tACS for Emotion Regulation and Attentional Bias in Adolescents With Nonsuicidal Self-Injury	0	12.4	09-06-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 17.3. Источник: archderm.jamanetwork.com.